NRD
ADPT icon

Nebula Research & Development’s Adaptive Biotechnologies ADPT Stock Holding History

Nebula Research & Development’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,011
Closed -$54.3K – 911
2024
Q2 		$54.3K Sell
15,011
-9,339
-38% -$29.6K 0.01% 778
2024
Q1 		$78.2K Sell
24,350
-40,153
-62% -$155K 0.02% 695
2023
Q4 		$316K Buy
64,503
+23,430
+57% +$107K 0.1% 415
2023
Q3 		$224K Buy
+41,073
New +$272K 0.12% 372

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Nebula Research & Development's ADPT Position: Q3 2024 in Review

Nebula Research & Development sold out of Adaptive Biotechnologies (ADPT) in Q3 2024, closing a stake of 15,011 shares — an estimated $54.3K sold.

Nebula Research & Development first reported a position in ADPT in Q3 2023 and held it in 4 quarters. The position peaked at $316K in Q4 2023. 187 funds tracked by Wall St. Rank hold ADPT as of Q3 2024.

  • Nebula Research & Development reported no remaining Adaptive Biotechnologies position as of Q3 2024 after selling out during the quarter.
  • Nebula Research & Development sold 15,011 Adaptive Biotechnologies shares in Q3 2024, an estimated $54.3K.
  • Nebula Research & Development first reported a position in Adaptive Biotechnologies in Q3 2023 and held it in 4 quarters.
  • Nebula Research & Development's Adaptive Biotechnologies position peaked at $316K in Q4 2023.
  • 187 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2024.

Based on Nebula Research & Development's 13F filing for Q3 2024, filed 14 Nov 2024.